The penicillin binding protein (PBP) genes dacA, dacB and ftsI from 14 cefuroxime-resistant (CXM R ) isolates and three clinical isolates with low CXM MIC for non-β-lactamase-producing Haemophilus influenzae type b were molecularly characterized. One strain, 5788, was used to transform H. influenzae Rd to CXM R for direct comparison of the pbps in the same genetic background. No obvious mutations in the dacA and dacB gene products could be associated with CXM R . One amino acid substitution in the ftsI gene product in particular, S357N, could give rise to CXM R . Sequence analysis from the CXM R transformants also implicated FtsI; in this case, the substitutions were V511A and R517H. To verify S357N substitution, the protein sequence of H. influenzae FtsI was threaded through the S. pneumoniae PBP 2X structure giving an average root mean square deviation of the α-carbon chains of 0.5 Å. The S357N substitution alters both the residue size and charge. One explanation for the contribution of S357N to CXM R is that the asparagine side-chain produces unfavourable steric hindrance with the side chain of Val-362 changing the torsion angles of the asparagine residue, which in turn may influence the position of the loop V362-P366 adjacent to the active site. Whilst other groups have examined the contribution of H. influenzae PBPs in ampicillin resistance, this is the first report analysing their role in CXM R .
Introduction
Haemophilus influenzae non-capsulate strains are usually responsible for non-invasive disease, causing local infections that are often associated with an underlying physiological or anatomical abnormality. The most common involve the respiratory tract: otitis media, sinusitis, and purulent episodes in patients with chronic obstructive pulmonary disease. Invasive infections (most commonly type b) include meningitis, epiglottitis, bacteraemia and pneumonia; however, with the advent of the Hib vaccine, cases associated with capsulated strains have diminished appreciably. 1 From its introduction in the early 1960s, ampicillin was regarded as the drug of choice for the treatment of infections in children, and proved to be effective against H. influenzae. In more recent times, cefuroxime (CXM) replaced ampicillin, particularly for community-acquired pneumonias due to ampicillin-resistant H. influenzae. Resistance to β-lactams is mediated by two mechanisms, namely, production of a constitutively expressed β-lactamase (often TEM but sometimes ROB-1) and mutation of the β-lactam targets, the penicillinbinding proteins (PBPs). Whilst β-lactamase production in H. influenzae has been well characterized, there is a paucity of information on alterations of PBPs in 'non-β-lactamaseproducing' H. influenzae (NBHI). The PBPs of H. influenzae were first characterized in 1981, when eight major PBPs were detected and the pattern of PBPs was demonstrably different from that of Escherichia coli. 2 Unfortunately, since this initial characterization, research on H. influenzae PBPs has been confused by the use of different naming systems by different research groups. 3, 4 The genome sequence of H. influenzae Rd was published in 1995 and studies have utilized this information to study PBP genes. 5 Ubukata et al. 6 ampicillin-resistant H. influenzae and reported differences in the ftsI gene product. Dabernet et al. 7 also determined the sequence of ftsI in almost 200 ampicillin-resistant isolates from different geographical locations and were able to correlate ampicillin resistance with particular mutations in ftsI. However, the conclusions of this study were not tested by transformation. In this study, we have analysed PBP genes linked to β-lactam resistance from other studies as possible mediators of cefuroxime resistance (CXM R ); namely dacA, dacB and ftsI. 3, 6, [8] [9] [10] [11] [12] This study was facilitated by the published genome sequence of H. influenzae Rd and identification of PBP genes based on their homologies to those in E. coli. 5 Mutations believed to be responsible for the CXM R phenotype were verified by transformation and gene sequencing. Protein modelling has been used to investigate the molecular significance of the ftsI mutations.
Materials and methods

Haemophilus isolates
Seventeen clinical isolates of H. influenzae type b were collected from patients at Southmead Hospital, Bristol, and the Royal United Hospital, Bath (Table 1) . Of these, three were cefuroxime sensitive (CXM S ) and 14 were CXM R . The isolates were confirmed as H. influenzae by API-NH testing. All isolates were tested for β-lactamase activity using the chromogenic substrate nitrocefin. 13 Strains were stored at -70°C in horse blood with 15% glycerol.
Media and antibiotics
The medium used for growth and determination of MICs was brain-heart infusion agar or broth supplemented with 10 µg of histidine, 10 µg of haemin and 15 µg of β-NAD per mL. Chocolate agar was used for routine culturing. Plate cultures were incubated at 37°C in an atmosphere of 5% CO 2 . The medium used for transformation was M-IV stage II medium. 14 Selective agar was brain-heart infusion agar supplemented with 10 µg of histidine, 10 µg of haemin and 15 µg of β-NAD per mL, plus an appropriate concentration of CXM. The antibiotics used in the study were CXM, ampicillin, kanamycin (Sigma, Poole, Dorset, UK) and imipenem (Merck, Sharpe & Dohme, Hoddesden, Herts, UK).
Determination of the MIC
The MICs of CXM and other β-lactams for clinical strains and transformants were determined by both Etest (AB Biodisk, Solna, Sweden) and agar dilution according to NCCLS guidelines. 15 MICs were determined in triplicate. The MIC was defined as the lowest concentration of antibiotic that totally inhibited growth of the inoculum.
DNA isolation
Strain 5788 was grown overnight on chocolate agar. After 24 h, the confluent bacterial lawn was suspended in 9.5 mL of TE buffer (10 mM Tris, 1 mM EDTA) to which were added 1 mg of proteinase K and 0.5 mL of 10% SDS. The cell min. An equal volume of chloroform/isoamyl alcohol (24:1) was added, the mixture shaken and centrifuged at 7000 rpm for 10 min at room temperature (Sigma 6K10). The aqueous layer was transferred to a clean tube, 0.6 vols of isopropanol added and gently mixed, and the tube was centrifuged at 13 000 rpm for 30 min at 4°C. The supernatant was poured off and the DNA pellet was suspended in 1 mL of 70% ethanol. The suspension was transferred to a 1.5 mL Eppendorf tube and spun in a microcentrifuge (Eppendorf 5415D) at 13 000 rpm for 15 min. The liquid was removed and the DNA pellet was washed with absolute alcohol and then dried at 30°C. The pellet was finally dissolved in 50 µL of diethyl pyrocarbonate (DEPC)-treated H 2 O. The quantity and quality of DNA were determined by analysing 10 µL on a 1% agarose gel. The DNA was stored at -20°C until needed.
Transformation
Transformation was based on the method of Herriott et al. 14 using M-IV stage II medium. The recipient H. influenzae Rd strain RM 132b -was grown overnight on chocolate agar. Five colonies were suspended in 1 mL of M-IV medium and incubated at 37°C for 100 min. The suspension was centrifuged at 13 000 rpm for 2 min, the supernatant removed and the cell pellet resuspended in 1 mL of M-IV medium; 10 µL of the DNA solution prepared as described was added to the cell suspension and the mixture incubated at 37°C for 30 min. DEPC-H 2 O was used as a negative control, and a kanamycin resistance plasmid (H. influenzae 132b -P5 construct) was used as the positive control; 16 1 in 10 and 1 in 100 dilutions of the DNA-treated cells (and controls) were plated on to selective agar containing 8 mg/L CXM. The positive control cells were plated on agar containing 20 mg/L kanamycin. Plates were incubated at 37°C for 24 h.
PCR amplification of PBP genes
PCR was carried out using a Hybaid MBS system (Hybaid, Middlesex, UK). H. influenzae strains were grown overnight on chocolate agar. Two colonies from each plate were suspended in 50 µL of DEPC-H 2 O and incubated at 95°C for 10 min. The suspension was centrifuged at 13 000 rpm for 10 min to give a crude cell lysate containing template DNA. To 10 µL of this lysate was added 5 µL of 10× buffer, 1 mM MgCl 2 , 0.1 mM each dNTP, 2 µM each primer and 2.5 U Taq DNA polymerase (MBI Fermentas) and water to give a total volume of 50 µL.
Primer pairs for the genes ftsI and dacB were designed from sequences in the GenBank nucleotide sequence database, and those for dacA from the sequence in the Institute for Genomic Research nucleotide database (Table 2) . Two different sequences were available for dacB; therefore, two primer sets were designed to amplify both alleles. All primers were from Sigma-Genosys Ltd, Pampisford, Cambs, UK and are listed in Table 2 .
Amplification conditions were 5 min at 95°C, followed by 30 cycles of 1 min at 95°C, 1 min at 60°C and 1 min at 72°C, followed by 5 min at 72°C. PCR products were analysed on 1% agarose gels to visualize them and were then purified using the Qiagen QIAquick PCR purification kit (Qiagen, Crawley, West Sussex, UK) according to the manufacturer's instructions.
Sequencing
Purified PCR products were sequenced at the Advanced Biotechnology Centre (Imperial College of Science, Technology and Medicine, London, UK). The internet-based programs ClustalW (www.ebi.ac.uk/clustalw) and the ExPASy Translate tool (www.expasy.ch/tools/dna.html) were used for sequence analysis. Both nucleotide and amino acid sequences were grouped according to the antibiotic susceptibility of the host strain and compared with a standard sequence obtained from H. influenzae Rd strain 132b, as well as with the published 
Protein modelling
A homology model of H. influenzae Rd PBP3 was produced. The primary amino acid sequence was threaded through the published crystal structure of S. pneumoniae PBP 2X (PDB entry code 1QME) using SWISS-MODEL. 17, 18 The resulting structure was inspected manually for unusual torsion angles and steric clashes. Torsion angles were changed manually to correct such conflicts. In particular, the torsion angles of Asn-357 were altered from their threaded values of φ = 179°, ψ = -162° and ω = -169° to φ = -168°, ψ = -167° and ω = 173°t o relieve steric hindrance between this residues side-chain and Val-362. The resulting structure was energy minimized with 20 steps of steepest descent and ≤100 of conjugate gradient minimization using the GROMOS96 program with parameter set 43B1, until the energy differential between steps was <0.01 kJ/mol. 19 
Protein docking
A solvent-accessible Connolly surface of the resultant homology model was created with Quantum Chemistry Program Exchange program 429 (University of Indiana, IN, USA) using a 1.4 Å solvent probe. 20 The CXM structure was docked into this surface using the flexX program (Tripos Inc., Cambridge, UK) with a 60 × 60 × 60 grid centred on the α-carbon atom of the active site residue Thr-328 and a grid spacing of 0.375 Å.
Results
β-Lactam MICs for H. influenzae clinical isolates and transformants
All CXM R isolates were also ampicillin resistant (>32 mg/L). Clinical isolate 4717, with a CXM MIC of 2 mg/L had an ampicillin MIC of 16 mg/L. CXM R transformants of H. influenzae strain Rd gave comparable CXM MIC results (32 mg/L) to that of the donor strain 5788 (16 mg/L). CXM MICs for clinical strains are shown in Table 1 .
PCR amplification and sequencing
PCR products were obtained using all primer sets, with the exception of the β-lactamase-negative control strain HIBLN, for which no products were obtained using primer sets targeted to dacB and dacA. The reason for this is unclear. Nucleotide sequences produced by PCR amplification were translated into predicted amino acid sequences and compared with the published H. influenzae Rd genome sequence.
Changes in the ftsI gene product in clinical isolates
Three amino acid substitutions in the ftsI gene product are common among the clinical CXM R isolates: A502T/V in 6/14 isolates; N526K in 11/14 and S357N (Table 1) . As A502T/V and N526K are also found in one of the isolates with a low MIC (2 mg/L) they are unlikely to be solely or primarily responsible for the CXM R phenotype. D350N substitution, found in one strain with low CXM MIC (4722) and one CXM R strain, as well as the HIBLN control strain, can also be discounted as being responsible for the CXM R phenotype. The substitution S357N was only found in CXM R strains. Of the CXM R isolates, only one, 5785, has the single amino acid substitution R501H. Seven have two substitutions, three have three substitutions and three have four substitutions (Table 1) . This variability was only apparent in strains with a CXM R phenotype where four substitutions were found in more than one CXM R isolate: S357N was seen in five isolates, R501H in three isolates and A502V and T528H in two each.
Changes in the dacA and dacB gene products in clinical isolates
The control strain HIBLN has 15 amino acid substitutions in the dacB gene product compared with that of the dacB gene product predicted from the RD genome sequence: S67P; N84G; Q88K; S95T; G102V; D105G; N107H; R120S; S125T; K189G; G192R; I194T; V213I; Y244S; N255D; Q262A. Fourteen of these (excluding R120S) are also present in the CXM S strain 4722. Four were also found in CXM R isolates: S67P; D84G in all bar one (5794, which does have a substitution here but to serine); N107H; and Q262A.
Amongst the CXM R isolates, four amino acid substitutions in DacB were each found once: V143I (5794); A172Ser (5804); A261V (5804); M306L (5783). Two substitutions (other than those previously mentioned that were common to both CXM R strains and those with low CXM MICs) were found in more than one isolate; S250N in two CXM R strains and R111S in four CXM R strains.
No changes in the amino acid sequences of the dacA gene products were detected among any of the isolates studied.
Analysis of CXM R transformants
CXM R transformants of H. influenzae Rd, designated TX1-TX6, were obtained using donor DNA from the CXM R isolate 5788 at a transformation frequency of ∼2 × 10 5 per µg of DNA. The cefuroxime MIC for the transformants increased from 0.25 to 32 mg/L, similar to the donor organism 5788. The amino acid changes found in FtsI in the CXM R transformants were compared with the FtsI sequence in H. influenzae Rd. The substitutions V511A and R517H found in FtsI in the donor strain 5788 were also found in FtsI in all six transformants. The dacA and dacB gene products in the CXM R transformants were identical to those of the CXM S recipient H. influenzae Rd.
Homology modelling
The identity between the amino acid sequences of S. pneumoniae PBP 2X and H. influenzae FtsI was 29%. This was sufficient to allow threading of the ftsI gene product between amino acids Q312 and S446. The initial threading produced an excellent fit within this region with an average root mean square deviation of the α-carbon chains of 0.5 Å. For the S357 structure, the α-carbon of Ser-357 was 11.7 Å from the active site region. On changing this from serine to asparagine, reducing steric hindrance with V362 and energy minimization the energy of this residue changed from -13 kJ/mol (serine) to -143 kJ/mol (asparagine). The distance of the α-carbon to the active site in this case was 11.4 Å. The values of the torsion angles for this residue were found to influence the position of the loop V362-P366 (sequence VDVAP), which lies adjacent to the active site. The structures of the homology model for both the Ser-357 and Asn-357 forms are shown in Figure 1 .
Cefuroxime docking
Cefuroxime docked into the active site region of the ftsI gene product in a conformation consistent with the binding of β-lactams to both PBPs and serine proteases. The lowest energy conformation is shown in Figure 2 .
Discussion
Ubukata et al. 6 showed that ampicillin-resistant non-β-lactamase-producing isolates of H. influenzae found in Japan carried mutations in their ftsI genes. The mutants were categorized into three distinct groups (I-III) according to which amino acid substitutions had occurred in the transpeptidase domain of the ftsI gene product. Group I mutants were those with an R517H change. Most of these also carried substitutions at D350N and S357N. Mutations in isolates assigned to Groups II and III generated an N526K change, as well as the D350N substitution. Most also have the S357N alteration. Group III isolates are distinguished by having three additional substitutions, M377I, S385T and L389F. All the isolates retained susceptibility to most cephalosporins, except cefaclor, to which they were resistant. In a more recent study, Dabernat et al. 7 investigated 109 clinical isolates of H. influenzae that were resistant to ampicillin and had reduced susceptibilities to cephalosporins. The isolates were basically grouped according to Ubukata et al., 6 but the majority (101) fell within class II. A single isolate was assigned to Group III, whereas the remainder (seven) were in class I. Class II was subdivided into four divisions, according to which amino acid substitutions, other than N526K, were found in the PBP encoded by ftsI. Hence, IIa isolates only have the N526K change, IIb also have an A502V alteration, with or without these other changes: G490Q, A437S, M377L, D350N. Group IIc isolates are distinguished by the N526K change coupled with an A502T substitution. Approximately half the isolates (12/25) in this subdivision were also found to have substitutions at position A368T or D350N. Group IId isolates comprised a single type with an I449V substitution, in addition to the D526N change. In both studies, quantitative changes in susceptibilities to β-lactams were not easily correlated with the alterations found in the PBP3 sequence.
The amino acid substitutions found in the present study (Table 1) do not fit neatly into the classification scheme described, although several of the substitutions reported by Ubukata et al. 6 and Dabernat et al. 7 (D350N, S357N, A368T , M377I, A502V/T, R517H and N526K) were found in our isolates. However, we also found substitutions at A337V, T443A, R501L, V511A, Y528H and T532S (Table 1) , which are previously unreported. Of the amino acid changes to the ftsI gene product previously reported to correlate with conversion to ampicillin resistance, three were detected in two of the lower CXM MIC isolates used in this study (Table 1) , specifically D350N, A502T and N526K. Accordingly, these alterations are not responsible for the CXM R phenotype, although they may act in concert with other substitutions that do confer high-level CMX R .
The substitutions that define group III, which confer significant resistance to cephem β-lactams, would be expected to be those most likely to be found in CXM R strains; however, this is not the case. Only one amino acid substitution in the PBP encoded by ftsI that was reported by Ubukata et al. 6 was found in more than one of the CXM R isolates and not in the strains with lower CXM MICs investigated in the present study, namely S357N. To understand the possible effect of this substitution on the enzyme, a molecular model of part of the transpeptidase encoded by H. influenzae ftsI was constructed, based on the structure of S. pneumoniae PBP2X. 18 The two amino acid sequences have 29% homology, which is sufficient to allow the region of the ftsI gene product to be modelled. PBP2X is a high molecular weight PBP with three domains: an N-terminal domain (amino acid residues 1-265), a central domain (amino acids 266-616) and a small C-terminal domain (amino acids 635-750). The active site serine, S337, is located in the central domain with a 3D structure comprising eight α-helices and five strands, which is similar to that of class A β-lactamases. The majority of penicillin-binding enzymes (high and low molecular weight PBPs and serine active site β-lactamases) have three amino acid motifs, S-X-X-L, S-X-N and K-S/T-G, which are highly conserved in sequence and spacing and are essential for function. 17 In PBP2X, these motifs are at S337-K340, S395-N397 and K547-G549; in the H. influenzae ftsI gene product the motifs are S326-T-V-K, S378-S-N and K512-T-G. When the appropriate section of the H. influenzae PBP was matched to that of PBP2X, a similar structure emerged in which the first two motifs aligned perfectly. Unfortunately, it was not possible to thread the H. influenzae PBP sequence beyond S446 because the level of amino acid identity with PBP2X falls below that required for modelling, so the third motif could not be incorporated into the hypothetical structure.
The fit between PBP2X and the ftsI gene product of H. influenzae in the region of S357 is very good, and this hypothetical structure allows us to predict the likely effect of an S357N substitution. This substitution alters both the residue size and charge at that point in the structure, whereas the distance between the new amino acid and the active site is predicted to decrease by only 0.3 Å. Such a distance precludes a direct interference with substrate binding by this residue. However, asparagine has a higher molecular volume than serine. One explanation for the contribution of this substitution to the CXM R phenotype is that the asparagine side-chain produces unfavourable steric hindrance with the side-chain of Val-362 (to which it is adjacent and in close proximity in our model). This hindrance can result in a change in the torsion angles of the asparagine residue, which in turn influences the position of the loop V362-P366, which is adjacent to the active site and may orient the loop so as to deny access of certain β-lactams to the transpeptidase active site of the enzyme (Figure 1) , so reducing the affinities of the PBPs for these β-lactams (Figure 2 ). Given that transpeptidase encoded by ftsI is essential to the cell, the amino acid alteration would not be expected to prevent interaction of the enzyme with its natural substrate, as such inhibition would be lethal. Mutations that change enzymes essential to cell survival so that they are less susceptible to a particular antibiotic(s) but retain essential function often impose a fitness cost on the bacterium; 21 however, the CXM R isolates grew as well on laboratory medium as strains with low CXM MICs.
With H. influenzae, mutation to CXM R appears generally to involve multiple amino acid substitutions in the ftsI gene product. Only one of the 14 CXM R isolates examined, strain 5785, showed a single change (R501H), and although the S357N substitution was that most commonly found (in five CXM R isolates), it was not detected in the majority of CXM R isolates. Two other substitutions in the ftsI gene product are likely to be important regarding CXM R ; namely, R501H (found in three isolates) and Y528H (found in two isolates). The first of these substitutions involves a major change of structure, from a dibasic amino acid to an aromatic one. Given that neither substitution was detected in previous studies that investigated mutations responsible for acquisition of resistance to ampicillin, 6, 7 it is not unreasonable to suggest that the R501H and Y528H changes specifically alter the interaction of the ftsI gene product with some cephalosporins.
There appears to be considerable allelic variation among the dacB genes in low and high CXM MIC clinical isolates of H. influenzae. Several differences in the amino acid sequences of the gene products, compared with the comparator gene product from H. influenzae Rd, were noted, as was the case for the Japanese ampicillin-resistant isolates analysed by Ubukata et al. 6 [S67P was found in 12 of 20 clinical isolates and in the β-lactamase-negative control strain; D84G was found in all clinical isolates except one (5794), which has a serine substitution instead, and also in the β-lactamasenegative control strain]. However, these substitutions were found in isolates with marked MICs, so are very unlikely to account for the resistant phenotype. Interestingly, the β-lactamase-negative control strain and the isolates with low CXM MICs show the greatest dacB allelic variation, indicating that the PBP encoded by dacB is not so tightly conserved as that encoded by ftsI. Interestingly, the Q270K substitution was found in seven of 10 CXM R isolates, including strain 5788, which was used as the DNA donor in transformation experiments; however, this change was not found in the CXM R transformants, i.e. strains TX1-TX6, and so is not likely to contribute to the resistant phenotype in the clinical isolates, a conclusion that agrees with that of Ubukata et al. 6 It was important to establish whether mutations in ftsI in a particular CXM R H. influenzae isolate alone are responsible for the resistance. Hence, the CXM S laboratory strain H. influenzae Rd was transformed to CXM R using DNA from the CXM R clinical isolate, 5788 (Table 1) . We reasoned that if the mutations in ftsI in the clinical isolate confer the CXM R phenotype, then all transformants should possess the same mutations, and the dacB gene should be unaltered. Isolate 5788 was chosen as the DNA donor because the two amino acid substitutions found in its ftsI gene product (V511A, R517H) are unique to this isolate. All six CXM R transformants possess ftsI alleles encoding gene products with the two amino acid substitutions, consistent with attribution of CXM R to these changes. In no case was dacB altered.
